Cargando…
Integrating pragmatic and implementation science randomized clinical trial approaches: a PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) analysis
BACKGROUND: Over the past two decades, pragmatic and implementation science clinical trial research methods have advanced substantially. Pragmatic and implementation studies have natural areas of overlap, particularly relating to the goal of using clinical trial data to leverage health care system p...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122352/ https://www.ncbi.nlm.nih.gov/pubmed/37085877 http://dx.doi.org/10.1186/s13063-023-07313-0 |
_version_ | 1785029474947956736 |
---|---|
author | Zatzick, Douglas Palinkas, Lawrence Chambers, David A. Whiteside, Lauren Moloney, Kathleen Engstrom, Allison Prater, Laura Russo, Joan Wang, Jin Abu, Khadija Iles-Shih, Matt Bulger, Eileen |
author_facet | Zatzick, Douglas Palinkas, Lawrence Chambers, David A. Whiteside, Lauren Moloney, Kathleen Engstrom, Allison Prater, Laura Russo, Joan Wang, Jin Abu, Khadija Iles-Shih, Matt Bulger, Eileen |
author_sort | Zatzick, Douglas |
collection | PubMed |
description | BACKGROUND: Over the past two decades, pragmatic and implementation science clinical trial research methods have advanced substantially. Pragmatic and implementation studies have natural areas of overlap, particularly relating to the goal of using clinical trial data to leverage health care system policy changes. Few investigations have addressed pragmatic and implementation science randomized trial methods development while also considering policy impact. METHODS: The investigation used the PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) and PRECIS-2-Provider Strategies (PRECIS-2-PS) tools to evaluate the design of two multisite randomized clinical trials that targeted patient-level effectiveness outcomes, provider-level practice changes and health care system policy. Seven raters received PRECIS-2 training and applied the tools in the coding of the two trials. Descriptive statistics were produced for both trials, and PRECIS-2 wheel diagrams were constructed. Interrater agreement was assessed with the Intraclass Correlation (ICC) and Kappa statistics. The Rapid Assessment Procedure Informed Clinical Ethnography (RAPICE) qualitative approach was applied to understanding integrative themes derived from the PRECIS-2 ratings and an end-of-study policy summit. RESULTS: The ICCs for the composite ratings across the patient and provider-focused PRECIS-2 domains ranged from 0.77 to 0.87, and the Kappa values ranged from 0.25 to 0.37, reflecting overall fair-to-good interrater agreement for both trials. All four PRECIS-2 wheels were rated more pragmatic than explanatory, with composite mean and median scores ≥ 4. Across trials, the primary intent-to-treat analysis domain was consistently rated most pragmatic (mean = 5.0, SD = 0), while the follow-up/data collection domain was rated most explanatory (mean range = 3.14–3.43, SD range = 0.49–0.69). RAPICE field notes identified themes related to potential PRECIS-2 training improvements, as well as policy themes related to using trial data to inform US trauma care system practice change; the policy themes were not captured by the PRECIS-2 ratings. CONCLUSIONS: The investigation documents that the PRECIS-2 and PRECIS-2-PS can be simultaneously used to feasibly and reliably characterize clinical trials with patient and provider-level targets. The integration of pragmatic and implementation science clinical trial research methods can be furthered by using common metrics such as the PRECIS-2 and PRECIS-2-PS. Future study could focus on clinical trial policy research methods development. TRIAL REGISTRATION: DO-SBIS ClinicalTrials.gov NCT00607620. registered on January 29, 2008. TSOS ClinicalTrials.gov NCT02655354, registered on July 27, 2015. |
format | Online Article Text |
id | pubmed-10122352 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101223522023-04-23 Integrating pragmatic and implementation science randomized clinical trial approaches: a PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) analysis Zatzick, Douglas Palinkas, Lawrence Chambers, David A. Whiteside, Lauren Moloney, Kathleen Engstrom, Allison Prater, Laura Russo, Joan Wang, Jin Abu, Khadija Iles-Shih, Matt Bulger, Eileen Trials Research BACKGROUND: Over the past two decades, pragmatic and implementation science clinical trial research methods have advanced substantially. Pragmatic and implementation studies have natural areas of overlap, particularly relating to the goal of using clinical trial data to leverage health care system policy changes. Few investigations have addressed pragmatic and implementation science randomized trial methods development while also considering policy impact. METHODS: The investigation used the PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) and PRECIS-2-Provider Strategies (PRECIS-2-PS) tools to evaluate the design of two multisite randomized clinical trials that targeted patient-level effectiveness outcomes, provider-level practice changes and health care system policy. Seven raters received PRECIS-2 training and applied the tools in the coding of the two trials. Descriptive statistics were produced for both trials, and PRECIS-2 wheel diagrams were constructed. Interrater agreement was assessed with the Intraclass Correlation (ICC) and Kappa statistics. The Rapid Assessment Procedure Informed Clinical Ethnography (RAPICE) qualitative approach was applied to understanding integrative themes derived from the PRECIS-2 ratings and an end-of-study policy summit. RESULTS: The ICCs for the composite ratings across the patient and provider-focused PRECIS-2 domains ranged from 0.77 to 0.87, and the Kappa values ranged from 0.25 to 0.37, reflecting overall fair-to-good interrater agreement for both trials. All four PRECIS-2 wheels were rated more pragmatic than explanatory, with composite mean and median scores ≥ 4. Across trials, the primary intent-to-treat analysis domain was consistently rated most pragmatic (mean = 5.0, SD = 0), while the follow-up/data collection domain was rated most explanatory (mean range = 3.14–3.43, SD range = 0.49–0.69). RAPICE field notes identified themes related to potential PRECIS-2 training improvements, as well as policy themes related to using trial data to inform US trauma care system practice change; the policy themes were not captured by the PRECIS-2 ratings. CONCLUSIONS: The investigation documents that the PRECIS-2 and PRECIS-2-PS can be simultaneously used to feasibly and reliably characterize clinical trials with patient and provider-level targets. The integration of pragmatic and implementation science clinical trial research methods can be furthered by using common metrics such as the PRECIS-2 and PRECIS-2-PS. Future study could focus on clinical trial policy research methods development. TRIAL REGISTRATION: DO-SBIS ClinicalTrials.gov NCT00607620. registered on January 29, 2008. TSOS ClinicalTrials.gov NCT02655354, registered on July 27, 2015. BioMed Central 2023-04-21 /pmc/articles/PMC10122352/ /pubmed/37085877 http://dx.doi.org/10.1186/s13063-023-07313-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zatzick, Douglas Palinkas, Lawrence Chambers, David A. Whiteside, Lauren Moloney, Kathleen Engstrom, Allison Prater, Laura Russo, Joan Wang, Jin Abu, Khadija Iles-Shih, Matt Bulger, Eileen Integrating pragmatic and implementation science randomized clinical trial approaches: a PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) analysis |
title | Integrating pragmatic and implementation science randomized clinical trial approaches: a PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) analysis |
title_full | Integrating pragmatic and implementation science randomized clinical trial approaches: a PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) analysis |
title_fullStr | Integrating pragmatic and implementation science randomized clinical trial approaches: a PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) analysis |
title_full_unstemmed | Integrating pragmatic and implementation science randomized clinical trial approaches: a PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) analysis |
title_short | Integrating pragmatic and implementation science randomized clinical trial approaches: a PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) analysis |
title_sort | integrating pragmatic and implementation science randomized clinical trial approaches: a pragmatic explanatory continuum indicator summary-2 (precis-2) analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122352/ https://www.ncbi.nlm.nih.gov/pubmed/37085877 http://dx.doi.org/10.1186/s13063-023-07313-0 |
work_keys_str_mv | AT zatzickdouglas integratingpragmaticandimplementationsciencerandomizedclinicaltrialapproachesapragmaticexplanatorycontinuumindicatorsummary2precis2analysis AT palinkaslawrence integratingpragmaticandimplementationsciencerandomizedclinicaltrialapproachesapragmaticexplanatorycontinuumindicatorsummary2precis2analysis AT chambersdavida integratingpragmaticandimplementationsciencerandomizedclinicaltrialapproachesapragmaticexplanatorycontinuumindicatorsummary2precis2analysis AT whitesidelauren integratingpragmaticandimplementationsciencerandomizedclinicaltrialapproachesapragmaticexplanatorycontinuumindicatorsummary2precis2analysis AT moloneykathleen integratingpragmaticandimplementationsciencerandomizedclinicaltrialapproachesapragmaticexplanatorycontinuumindicatorsummary2precis2analysis AT engstromallison integratingpragmaticandimplementationsciencerandomizedclinicaltrialapproachesapragmaticexplanatorycontinuumindicatorsummary2precis2analysis AT praterlaura integratingpragmaticandimplementationsciencerandomizedclinicaltrialapproachesapragmaticexplanatorycontinuumindicatorsummary2precis2analysis AT russojoan integratingpragmaticandimplementationsciencerandomizedclinicaltrialapproachesapragmaticexplanatorycontinuumindicatorsummary2precis2analysis AT wangjin integratingpragmaticandimplementationsciencerandomizedclinicaltrialapproachesapragmaticexplanatorycontinuumindicatorsummary2precis2analysis AT abukhadija integratingpragmaticandimplementationsciencerandomizedclinicaltrialapproachesapragmaticexplanatorycontinuumindicatorsummary2precis2analysis AT ilesshihmatt integratingpragmaticandimplementationsciencerandomizedclinicaltrialapproachesapragmaticexplanatorycontinuumindicatorsummary2precis2analysis AT bulgereileen integratingpragmaticandimplementationsciencerandomizedclinicaltrialapproachesapragmaticexplanatorycontinuumindicatorsummary2precis2analysis |